These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.
News & Analysis: Precision BioSciences Inc
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
Find out why one of these stocks lost more than half its value.
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
The gene-editing company rallied investors around intriguing clinical data released earlier this month, and the rally hasn't stopped.
The media has gotten a little carried away (again) by overlooking a simple technical flaw in the latest gene editing tool.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?